Pharmaceuticals, Biotechnology and Life Sciences
Genflow Biosciences, the only publicly listed longevity company in Europe, has launched a new development program in ophthalmology, focused on…
Valneva SE, a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases,…
Oncodesign Services has appointed Dr. Aidan Synnott as chief executive officer, to help strengthen its position as a trusted partner in drug discovery. The appointment reflects the company’s commitment to deepen client collaboration, enhance the quality of its science, and anticipate the evolving needs of the biopharma industry.
Evestia Clinical is kicking off with new identity of EMAS Pharma, as it sets its sights on rapid growth as a…
A UK biotech company Aelius Biotech whose unique laboratory gut model is used to trial new drugs and foodstuffs without the need for animal testing has raised a further £750,000 from the North East Venture Fund, supported by the European Regional Development Fund and managed by Mercia Ventures.
High Force Research, a leading provider of specialist chemical R&D and manufacturing services, has appointed Dr Nathalie Huther as its new Chief Commercial Officer (CCO), after the company’s most recent Management Buyout (MBO).
CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price…
Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, today announces the appointment of Soumya Chandramouli as Chief Financial Officer (CFO).
Soumya Chandramouli has 25 years’ experience in financial management, most recently as Chief Financial Officer of IBA Group, a listed company in the medical device and healthcare sectors with revenues of circa €500M, where she led a team of 50+ staff across multiple entities in North America and EMEA. Soumya recently contributed to a €93M private equity backed fundraising of a spin-off in the life sciences sector in Belgium.
Soumya’s experience in a globally deployed organization will be vital in supporting Novadip as it aims to become a commercial company with NVD003, its first autologous product, in the US, EU and Japanese markets in 2027, to address rare pediatric indications including Congenital Pseudarthrosis of the Tibia (CPT).
Novadip is planning a €50M Series C funding round with the aim of conducting two phase 3 trials with NVD003 and a Phase 2b/3 trial with NVDX3. The first patient in the NVD003 Phase 3 study in CPT will be enrolled in Q2, 2025. With access to the FDA’s Priority Review Voucher (>$150M), NVD003 could generate significant revenues. From 2027 to 2029, the commercial deployment of NVD003 for CPT will be associated with an increase in its clinical indications. Novadip’s Phase 2b/3 trial with NVDX3, its allogenic cell-derived product, will target spine fusion and trauma indications. The company is also developing its cell-free platform for the treatment of bone tumors and skin healing.
The Danish-founded biotech company Pila Pharma said Wednesday in a press release it looks to secure a partnership or acquisition…
The European Commission (EC) has granted approval to Breyanzi® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, Bristol Myers Squibb said Friday.